Nature Reviews Clinical Oncology, Published online: 10 November 2026; doi:10.1038/s41571-026-01230-2 The randomized phase II ImmunoPRISM trial has shown encouraging efficacy of the B cell maturation antigen-targeted bispecific T cell engager teclistamab in high-risk smouldering multiple myeloma, although several aspects constrain interpretation of the results. Herein, I discuss aspects that should be addressed in future research, such as patient selection, treatment duration, clinically relevant end points and adequate treatment in the control arm, to establish whether deep responses translate into durable prevention of progression with an acceptable benefit–risk profile.
María-Victoria Mateos. T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?. // Nature Reviews Clinical Oncology. – 2026. – DOI: 10.1038/s41571-026-01230-2. – URL: https://www.nature.com/articles/s41571-026-01230-2
María-Victoria Mateos (2026). T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01230-2
María-Victoria Mateos. “T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?.” Nature Reviews Clinical Oncology, 2026. doi:10.1038/s41571-026-01230-2.
@article{Mateos2026,
title = {T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?},
author = {Mateos, María-Victoria},
journal = {Nature Reviews Clinical Oncology},
year = {2026},
doi = {10.1038/s41571-026-01230-2},
url = {https://www.nature.com/articles/s41571-026-01230-2}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment